Anaphylaxis: Diagnosis, Management, and Biphasic Reactions

🔑 KEY CONCEPT: Anaphylaxis is a severe, life-threatening, generalized or systemic hypersensitivity reaction characterized by rapidly developing airway, breathing, and/or circulation problems usually associated with skin and mucosal changes.

Pathophysiology Anaphylaxis involves rapid degranulation of mast cells and basophils, leading to massive release of inflammatory mediators including histamine, leukotrienes, prostaglandins, and platelet-activating factor. This cascade results in:

• Increased vascular permeability and vasodilation
• Smooth muscle contraction (bronchospasm)
• Increased mucus secretion
• Cardiac effects (increased heart rate, decreased contractility)
• Coagulation abnormalities

Types of Anaphylactic Reactions

⚡ HIGH-YIELD: The severity and speed of anaphylaxis depend on the route of exposure, with intravenous administration causing the most rapid and severe reactions.

Common Triggers

• Foods: Peanuts, tree nuts, shellfish, fish, milk, eggs, sesame
• Medications: Beta-lactam antibiotics, NSAIDs, neuromuscular blocking agents
• Insect stings: Hymenoptera (bees, wasps, hornets, ants)
• Other: Latex, exercise, cold exposure

Risk Factors for Severe Anaphylaxis

• Asthma (especially poorly controlled)
• Previous severe anaphylactic reaction
• Concurrent use of ACE inhibitors or beta-blockers
• Elevated baseline tryptase levels
• Age (adolescents and young adults at higher risk for fatal food anaphylaxis)

Understanding these mechanisms is crucial for rapid recognition and appropriate management of anaphylactic reactions.

🔬 DIAGNOSIS: Anaphylaxis is highly likely when any one of the following three criteria is fulfilled:

Criterion 1: Acute onset of illness (minutes to several hours) with involvement of skin, mucosal tissue, or both AND at least one of:

• Respiratory compromise (dyspnea, wheeze, stridor, hypoxemia)
• Reduced blood pressure or symptoms of end-organ dysfunction

Criterion 2: Two or more of the following that occur rapidly after exposure to a likely allergen:

• Skin-mucosal tissue involvement
• Respiratory compromise
• Reduced blood pressure or symptoms of end-organ dysfunction
• Persistent gastrointestinal symptoms

Criterion 3: Reduced blood pressure after exposure to a known allergen:

• Adults: Systolic BP <90 mmHg or >30% decrease from baseline
• Children: Age-specific low systolic BP or >30% decrease from baseline

Clinical Manifestations by System

Skin/Mucosa (80-90%): Respiratory (70%): • Urticaria • Dyspnea • Angioedema • Wheeze • Flushing • Stridor • Pruritus • Cough • Rhinorrhea

Cardiovascular (45%): Gastrointestinal (30-45%): • Hypotension • Nausea/vomiting • Tachycardia • Diarrhea • Cardiac arrest • Cramping • Arrhythmias • Dysphagia

Neurological (15%): • Confusion • Dizziness • Loss of consciousness

⚠️ PEARL: Up to 10% of anaphylactic reactions may present without cutaneous manifestations, particularly in cases involving cardiovascular collapse.

Severity Grading (Ring and Messmer Classification)

Differential Diagnosis

• Vasovagal reaction (bradycardia, pallor)
• Panic attack (normal vital signs)
• Hereditary angioedema (no urticaria)
• Mastocytosis (elevated baseline tryptase)
• Scombroid poisoning (histamine-like symptoms)

Rapid clinical assessment and pattern recognition are essential for timely intervention.

🔬 DIAGNOSIS: Laboratory testing supports the clinical diagnosis of anaphylaxis but should never delay treatment.

Serum Tryptase

• Acute tryptase: Obtain within 30 minutes to 3 hours after symptom onset
• Normal range: <11.5 ng/mL (mcg/L)
• Interpretation:
  • Elevation >20 ng/mL or >1.2 × baseline + 2 ng/mL suggests anaphylaxis
  • Peak levels occur 30-90 minutes after reaction onset
  • Sensitivity: ~50% for anaphylaxis, higher for drug/insect sting reactions
  • May remain normal in food-induced anaphylaxis

Baseline Tryptase

• Obtain 24 hours to 2 weeks after resolution
• Elevated baseline (>20 ng/mL) suggests mastocytosis
• Useful for calculating significant acute elevation

Other Laboratory Markers

⚡ HIGH-YIELD: Tryptase levels may be normal in up to 50% of anaphylactic reactions, particularly those triggered by foods.

Additional Laboratory Studies

• Complete Blood Count: May show hemoconcentration from capillary leak
• Comprehensive Metabolic Panel: Assess for acute kidney injury
• Arterial Blood Gas: Evaluate respiratory status and acid-base balance
• Cardiac biomarkers: If cardiovascular involvement suspected
• Coagulation studies: DIC may occur in severe cases

Post-Acute Testing (After Resolution)

• Allergen-specific IgE testing: Identify triggering allergens
• Skin testing: Performed 4-6 weeks after reaction (avoid during refractory period)
• Component-resolved diagnostics: For complex cases with multiple sensitivities

When to Suspect Mastocytosis

• Elevated baseline tryptase (>20 ng/mL)
• Recurrent anaphylaxis without clear trigger
• Unusual triggers (alcohol, NSAIDs, heat)
• Associated symptoms: flushing, diarrhea, bone pain

💊 TREATMENT CORRELATION: Elevated tryptase levels may predict more severe reactions and increased risk of biphasic anaphylaxis.

Laboratory testing provides valuable confirmatory evidence and helps guide long-term management strategies.

💊 TREATMENT: Epinephrine is the first-line treatment for anaphylaxis and should be administered immediately upon recognition.

Mechanism of Action

• Alpha-1 agonism: Vasoconstriction, reduces capillary leak
• Beta-1 agonism: Positive inotropic and chronotropic effects
• Beta-2 agonism: Bronchodilation, inhibits mediator release

Dosing and Administration

Intramuscular Route (Preferred)

Administration Technique

• Inject into anterolateral thigh (vastus lateralis)
• Hold firmly for 3-10 seconds
• Can inject through clothing
• Massage injection site after removal

⚡ HIGH-YIELD: The anterolateral thigh provides the most reliable absorption compared to deltoid or subcutaneous routes.

Intravenous Epinephrine (Severe Cases) Indications:

• Cardiac arrest
• Severe hypotension unresponsive to IM epinephrine
• Inability to establish vascular access for fluids

IV Dosing Protocol

Bolus: 1-10 mcg/kg (0.1-1 mL of 1:100,000) Infusion: 0.1-1 mcg/kg/min

Preparation:

• Mix 1 mg epinephrine in 250 mL normal saline
• Concentration: 4 mcg/mL
• Start at 1-4 mcg/min, titrate to effect

Timing and Repeat Dosing

• Administer within first few minutes of recognition
• Repeat IM dose every 5-15 minutes if symptoms persist
• Up to 10-20% of patients require second dose
• No absolute contraindications in anaphylaxis

Special Considerations

Patients on Beta-blockers

• May have refractory hypotension and bradycardia
• Consider glucagon 1-2 mg IV/IM every 5 minutes
• Higher doses of epinephrine may be required

Patients on ACE Inhibitors

• Increased risk of severe anaphylaxis
• May have refractory hypotension
• Standard epinephrine dosing applies

Pregnancy

• Epinephrine is safe and indicated
• Hypotension threatens fetal perfusion
• No dose adjustment necessary

⚠️ PEARL: Delayed epinephrine administration (>30 minutes) is associated with increased risk of fatal outcomes.

Common Errors

• Using subcutaneous route (slower absorption)
• Inadequate dosing
• Delay in administration while obtaining IV access
• Substituting antihistamines as first-line therapy

Prompt epinephrine administration is the cornerstone of anaphylaxis management and can be life-saving when given appropriately.

💊 TREATMENT: While epinephrine is first-line therapy, supportive care and adjunctive treatments are crucial for optimal outcomes.

Immediate Supportive Measures

Airway Management

• Position patient supine with legs elevated (unless respiratory distress)
• High-flow oxygen (15 L/min via non-rebreather mask)
• Consider early intubation for:
  • Upper airway edema
  • Stridor
  • Severe respiratory distress
  • Impending respiratory failure

Fluid Resuscitation

• Large-bore IV access (2 sites preferred)
• Normal saline 1-2 L bolus in adults (20 mL/kg in children)
• May require up to 4-6 L in severe cases due to capillary leak
• Monitor for fluid overload in elderly/cardiac patients

Adjunctive Medications

⚡ HIGH-YIELD: Antihistamines and corticosteroids are NOT first-line treatments and should never delay epinephrine administration.

Refractory Hypotension Management

Step 1: Repeat epinephrine IM/IV Step 2: Aggressive fluid resuscitation Step 3: Consider vasopressors • Norepinephrine 0.1-2 mcg/kg/min • Vasopressin 0.03-0.04 units/min • Dopamine 5-20 mcg/kg/min Step 4: Methylene blue (last resort) • 1-2 mg/kg IV for refractory shock

Monitoring Requirements

• Continuous cardiac monitoring
• Blood pressure every 5-10 minutes initially
• Oxygen saturation monitoring
• Hourly urine output
• Serial arterial blood gases if severe

Disposition and Observation Period

Observation Criteria

• Mild reactions: 4-6 hours minimum
• Moderate to severe: 8-24 hours
• Risk factors for biphasic reaction: Extended observation

Discharge Criteria

• Symptom resolution
• Hemodynamic stability
• Normal oxygen saturation
• Adequate response to treatment
• Reliable follow-up arranged

Discharge Planning

• Epinephrine auto-injector prescription (2 devices)
• Medical alert bracelet/identification
• Anaphylaxis action plan
• Allergy specialist referral
• Trigger avoidance education

⚠️ PEARL: Patients who receive epinephrine for anaphylaxis should always be transported to an emergency department for observation and further management.

Special Populations

• Elderly: Increased cardiovascular complications
• Pregnant: Consider left lateral positioning
• Pediatric: Weight-based dosing, consider child life support

Comprehensive supportive care alongside epinephrine maximizes patient outcomes and reduces complications.

⚡ HIGH-YIELD: Biphasic anaphylaxis occurs in 5-20% of cases, representing a second wave of symptoms after apparent resolution of the initial reaction.

Definition and Characteristics Biphasic anaphylaxis involves recurrence of anaphylactic symptoms after a symptom-free interval, typically occurring within 4-12 hours (range: 30 minutes to 72 hours) of the initial reaction.

Clinical Features of Biphasic Reactions

• May be milder, equal, or more severe than initial reaction
• Often presents with similar symptom pattern
• Cardiovascular manifestations more common in late phase
• May occur without re-exposure to triggering allergen
• Can be fatal, especially when occurring outside medical facility

Risk Factors for Biphasic Anaphylaxis

Pathophysiology Multiple theories exist:

• Incomplete mediator clearance: Persistent inflammatory cascade
• Late-phase allergic reaction: IgE-mediated late-phase response
• Inadequate initial treatment: Insufficient epinephrine leading to ongoing reaction
• Complement activation: Secondary inflammatory pathway activation

⚠️ PEARL: The asymptomatic interval between phases can create false reassurance, emphasizing the need for extended observation.

Prevention Strategies

Immediate Management

Early Epinephrine Administration: • Within 5-10 minutes of symptom onset • Adequate dosing (0.3-0.5 mg IM) • Repeat dosing as needed

Aggressive Supportive Care: • IV fluid resuscitation • Continuous monitoring • Prompt treatment of recurrent symptoms

Corticosteroid Role

• Traditional belief: May prevent biphasic reactions
• Current evidence: Limited proof of efficacy
• Recommended dosing: Methylprednisolone 1-2 mg/kg IV
• Timing: Administer early in acute phase

Observation Protocols

Standard Observation Periods

• Low risk: 4-6 hours
• Moderate risk: 8-12 hours
• High risk: 12-24 hours

Extended Observation Indications

• Multiple epinephrine doses required
• Severe initial reaction with hypotension
• Delayed presentation (>2 hours from exposure)
• History of biphasic reaction
• Social factors (remote location, limited access to care)

Monitoring During Observation

• Vital signs every 30 minutes initially, then hourly
• Continuous cardiac monitoring for severe cases
• Serial physical examinations
• Patient/family education on symptom recognition

Discharge Criteria After Observation

• Complete symptom resolution for minimum observation period
• Hemodynamic stability
• Adequate social support and follow-up
• Patient understanding of recurrence risk
• Access to emergency care if symptoms return

Patient Education

• Inform patients about 24-72 hour risk window
• Provide clear instructions for emergency care access
• Emphasize importance of carrying epinephrine auto-injectors
• Schedule urgent allergy follow-up

💊 TREATMENT PEARL: Patients with risk factors for biphasic reactions should be strongly considered for prolonged observation or admission, even if asymptomatic.

Understanding biphasic anaphylaxis patterns helps optimize observation protocols and reduce preventable deaths from delayed reactions.

🔑 KEY CONCEPT: Long-term management focuses on trigger identification, avoidance strategies, emergency preparedness, and consideration for desensitization therapy.

Allergen Identification and Testing

Timing of Testing

• Wait 4-6 weeks after acute reaction (refractory period)
• Earlier testing may yield false negatives
• Obtain detailed history of potential triggers

Testing Modalities

Emergency Action Plans

Epinephrine Auto-Injector Prescription

• Always prescribe 2 devices (home, school/work)
• Train patient, family, and caregivers on use
• Check expiration dates regularly (replace every 12-18 months)
• Consider temperature-stable storage

Action Plan Components

1. RECOGNIZE symptoms of anaphylaxis
2. INJECT epinephrine immediately
3. CALL 911 emergency services
4. REPEAT epinephrine in 5-15 minutes if symptoms persist
5. GO to emergency department even if symptoms improve
6. NOTIFY emergency contacts

Trigger Avoidance Strategies

Food Allergies

• Strict avoidance of trigger foods
• Read all ingredient labels carefully
• Restaurant communication strategies
• Cross-contamination prevention
• Emergency medication availability

Drug Allergies

• Medical alert identification
• Communication with all healthcare providers
• Alternative medication lists
• Premedication protocols when necessary

Insect Sting Prevention

• Avoid outdoor activities during peak seasons
• Wear protective clothing
• Avoid strong fragrances and bright colors
• Consider venom immunotherapy

Immunotherapy Considerations

Venom Immunotherapy (VIT)

• Indications: Systemic reactions to Hymenoptera stings
• Efficacy: 95-98% effective in preventing severe reactions
• Duration: Typically 3-5 years
• Contraindications: Severe asthma, beta-blocker therapy

Food Immunotherapy

• Oral Immunotherapy (OIT): Gradual dose escalation
• Epicutaneous Immunotherapy: Patch-based delivery
• Sublingual Immunotherapy: Under-tongue administration
• Status: Investigational for most foods, FDA-approved peanut OIT available

⚡ HIGH-YIELD: Venom immunotherapy is highly effective and recommended for patients with systemic reactions to insect stings.

Special Situations

Perioperative Management

• Detailed allergy history
• Consider premedication protocols
• Alternative anesthetic agents
• Emergency preparedness in OR

Pregnancy and Anaphylaxis

• Continue trigger avoidance
• Epinephrine safe in pregnancy
• Obstetric consultation for delivery planning
• Postpartum continuation of precautions

Follow-up Care

Specialist Referral

• All patients with anaphylaxis should see an allergist
• Timing: Within 2-4 weeks of reaction
• Brings: Detailed reaction history, medications, photos if available

Monitoring and Assessment

• Annual review of action plans
• Auto-injector technique assessment
• Trigger avoidance strategies
• Quality of life evaluation
• Consideration for therapy modifications

💊 TREATMENT PEARL: Patients with idiopathic anaphylaxis may benefit from prophylactic antihistamines and should be evaluated for underlying mastocytosis.

Patient Education Priorities

• Recognition of early warning signs
• Proper auto-injector technique
• When to seek emergency care
• Travel considerations and precautions
• School/workplace emergency planning

Comprehensive long-term management reduces recurrence risk and improves quality of life while maintaining preparedness for potential future reactions.